EUVIMEDEUVIMED entdecken
Vergleichsstudie

Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System

Bo Xu iD, Tianqiao Zhang iD, Bo Kang, Xiongwen Yang, Shaoqian Li, Jixiang Chen, Zunbo He, Jiecan Zhou iD

Cardiovascular Drugs and Therapy · 2025

DOI: 10.1007/s10557-024-07653-2 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Bo Xu und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical Scho…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Death, Sudden, Cardiac, Adverse Drug Reaction Reporting Systems, Hypoglycemic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: NSFC, Natural Science Foundation of Hunan Province, Hunan Provincial Health High-Level Talent Scientific Research Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsDeath, Sudden, CardiacAdverse Drug Reaction Reporting SystemsHypoglycemic AgentsArrhythmias, CardiacHumansUnited StatesUnited States Food and Drug AdministrationPharmacovigilanceDatabases, FactualData MiningRisk AssessmentRisk FactorsMaleFemaleMiddle Aged

Stichwörter der Autor:innen

FDA Adverse Event Reporting SystemSodium-glucose cotransporter 2 inhibitorsSudden cardiac deathVentricular arrhythmias

Substanzen

Sodium-Glucose Transporter 2 InhibitorsHypoglycemic Agents

Autor:innen und Institutionen

  • The First Affiliated Hospital, Hunan Provincial Clinical Medical Research Center for Drug Evaluation of Major Chronic Diseases, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
  • The First Affiliated Hospital, Hengyang Clinical Pharmacology Research Center, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
  • The First Affiliated Hospital, Hengyang Key Laboratory of Clinical Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
  • The First Affiliated Hospital, Pharmacy Department, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
  • School of Pharmaceutical Science, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
  • The Affiliated Nanhua Hospital, Department of Docimasiology, Hengyang Medical School, University of South China, Hengyang, 421002, Hunan, China.

ORCID-Profile: Bo Xu, Tianqiao Zhang, Jiecan Zhou

Förderung

  • NSFC
  • Natural Science Foundation of Hunan Province
  • Hunan Provincial Health High-Level Talent Scientific Research Project
  • Hunan Province Clinical Medical Technology Innovation Guidance Project
  • Hunan Provincial Clinical Medical Research Center for Drug Evaluation of major chronic diseases
  • The science and technology innovation Program of Hunan Province

Zitieren

APA

Xu, B., Zhang, T., Kang, B., Yang, X., Li, S., Chen, J., He, Z., & Zhou, J. (2025). Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07653-2

Vancouver

Xu B, Zhang T, Kang B, Yang X, Li S, Chen J, et al. Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07653-2

BibTeX
@article{Xu2025,
  author = {Xu, Bo and Zhang, Tianqiao and Kang, Bo and Yang, Xiongwen and Li, Shaoqian and Chen, Jixiang and He, Zunbo and Zhou, Jiecan},
  title = {Investigating Sodium-Glucose Cotransporter 2 Inhibitors Versus Other Glucose-Lowering Drugs on Ventricular Arrhythmias or Sudden Cardiac Death Using the US FDA Adverse Event Reporting System},
  journal = {Cardiovascular Drugs and Therapy},
  year = {2025},
  doi = {10.1007/s10557-024-07653-2}
}
Kostenlos starten →